A bispecific antibody can bind to two different antigens with the two arms of the antibody. We have established bispecific antibody technology to enable commercial level manufacturing. We have discovered bispecific IgG antibody recognizing FIXa and FX, which mimics the function of FVIII, for the treatment of haemophilia A. Our bispecific antibody technology has been applied to create FDA-approved product, HEMLIBRA® (emicizumab), the world first recombinant bispecific IgG antibody, and we have multiple bispecific antibodies that are now being tested in clinical study and in the drug discovery stage.
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Nat Med. 2012 Oct;18(10):1570-4.